Back to Journals » Research and Reports in Urology » Volume 4

Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing

Authors Millholland, Li, Fernandez C, Shuber A

Received 7 April 2012

Accepted for publication 18 May 2012

Published 27 June 2012 Volume 2012:4 Pages 33—40

DOI https://doi.org/10.2147/RRU.S32736

Review by Single-blind

Peer reviewer comments 2


John M Millholland, Shuqiang Li, Cecilia A Fernandez, Anthony P Shuber

Predictive Biosciences Inc, Lexington, MA, USA

Abstract: Biological fluid-based noninvasive biomarker assays for monitoring and diagnosing disease are clinically powerful. A major technical hurdle for developing these assays is the requirement of high analytical sensitivity so that biomarkers present at very low levels can be consistently detected. In the case of biological fluid-based cancer diagnostic assays, sensitivities similar to those of tissue-based assays are difficult to achieve with DNA markers due to the high abundance of normal DNA background present in the sample. Here we describe a new urine-based assay that uses ultradeep sequencing technology to detect single mutant molecules of fibroblast growth factor receptor 3 (FGFR3) DNA that are indicative of bladder cancer. Detection of FGFR3 mutations in urine would provide clinicians with a noninvasive means of diagnosing early-stage bladder cancer. The single-molecule assay detects FGFR3 mutant DNA when present at as low as 0.02% of total urine DNA and results in 91% concordance with the frequency that FGFR3 mutations are detected in bladder cancer tumors, significantly improving diagnostic performance. To our knowledge, this is the first practical application of next-generation sequencing technology for noninvasive cancer diagnostics.

Keywords: FGFR3, mutation, urine, single molecule, sequencing, bladder cancer

Corrigendum for this paper has been published

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]